search
Back to results

(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention) (REDUCED)

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Phase 3
Locations
Turkey
Study Type
Interventional
Intervention
coronary intervention
Sponsored by
Bursa Postgraduate Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring percutaneous coronary intervention, low dose intracoronary heparin

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patients; who have planned elective PCI and have had written informed consent for participation to study.
  • The native coronary artery;

    • lesion with narrowing >=70%,
    • lesion without thrombus
    • no left main coronary artery (LMCA) lesion
    • no chronic total occlusion lesion

Exclusion Criteria:

  • Patients have allergy for acetylsalicylic acid (ASA), Clopidogrel and heparin
  • Patients who performed primary PCI
  • Patients with acute coronary syndrome
  • Patients with have a history of myocardial infarction (MI) for two weeks
  • Patients who were use UFH or low molecular weight heparin (LMWH) for 24 hours
  • Patients on warfarin therapy
  • Patients who have bleeding diathesis, or have high risk for bleeding.

Sites / Locations

  • Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Low dose intracoronary heparin

Standard treatment arm

Arm Description

Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin

Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin

Outcomes

Primary Outcome Measures

Major Adverse Cardiac Events
Major Adverse Cardiac Event

Secondary Outcome Measures

Full Information

First Posted
December 11, 2009
Last Updated
December 24, 2013
Sponsor
Bursa Postgraduate Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01031095
Brief Title
(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
Acronym
REDUCED
Official Title
A RandomisED StUdy Comparing Standard Systemic Anticoagulation ThErapy to Low Dose Intracoronary Anticoagulation Therapy for Elective Percutaneous Coronary Intervention
Study Type
Interventional

2. Study Status

Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bursa Postgraduate Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The hypothesis: Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.
Detailed Description
Aim: Primary objective:To evaluate the efficiency and safety of low dose intracoronary unfractioned heparin (UFH) on elective percutaneous coronary intervention (PCI). Secondary objective: To evaluate the effect of low dose intracoronary UFH on myocardial ischemia after PCI. To evaluate the effect of low dose intracoronary UFH on bleeding complications after PCI. To evaluate the cost-effectivity of low dose intracoronary UFH on elective PCI Study central: Bursa Postgraduate Hospital, Cardiology Clinic Study population: we planned to enrol 200 patients. Patients will randomise in two groups (control group:100 patients, study group:100 patients) Study works:-Write case report form for all patients Control for inclusion criteria Demographic data (age, gender) Height, weight, BMI and glomerular filtration rate (GFR) Risk factors laboratory data (biochemical and hematologic) Medication history Echocardiographic data Angiographic data Procedure time PCI data(vessel diameter, stent diameter, lesion and stent length, performed percutaneous transluminal coronary angioplasty (PTCA) or not, etc) Before and after procedure (activated clotting time) ACT value Before and after procedure troponin I (TnI) and Creatine kinase MB (CKMB) levels Note complication (MACE, bleeding, hematoma etc) Note femoral compression time. 4 weeks later note the first control data. Six months later note the second control data.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
percutaneous coronary intervention, low dose intracoronary heparin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low dose intracoronary heparin
Arm Type
Experimental
Arm Description
Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
Arm Title
Standard treatment arm
Arm Type
Active Comparator
Arm Description
Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
Intervention Type
Other
Intervention Name(s)
coronary intervention
Intervention Description
elective coronary intervention
Primary Outcome Measure Information:
Title
Major Adverse Cardiac Events
Time Frame
30 days
Title
Major Adverse Cardiac Event
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patients; who have planned elective PCI and have had written informed consent for participation to study. The native coronary artery; lesion with narrowing >=70%, lesion without thrombus no left main coronary artery (LMCA) lesion no chronic total occlusion lesion Exclusion Criteria: Patients have allergy for acetylsalicylic acid (ASA), Clopidogrel and heparin Patients who performed primary PCI Patients with acute coronary syndrome Patients with have a history of myocardial infarction (MI) for two weeks Patients who were use UFH or low molecular weight heparin (LMWH) for 24 hours Patients on warfarin therapy Patients who have bleeding diathesis, or have high risk for bleeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hasan Arı, MD
Organizational Affiliation
Bursa Postgraduate Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
City
Bursa
ZIP/Postal Code
16320
Country
Turkey

12. IPD Sharing Statement

Citations:
PubMed Identifier
18929239
Citation
Stabile E, Nammas W, Salemme L, Sorropago G, Cioppa A, Tesorio T, Ambrosini V, Campopiano E, Popusoi G, Biondi Zoccai G, Rubino P. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol. 2008 Oct 14;52(16):1293-8. doi: 10.1016/j.jacc.2008.07.026.
Results Reference
background
PubMed Identifier
25643432
Citation
Ari H, Kivac E, Ari S, Emlek N, Cetinkaya S, Celiloglu N, Sarigul OY, Aydin C, Akkaya M, Koca V, Bozat T, Gurdogan M. The REDUCED (a RandomisED stUdy Comparing standard systemic anticoagulation thErapy to low Dose intracoronary anticoagulation therapy for elective percutaneous coronary intervention) trial. A novel pharmacologic regime for elective percutaneous coronary intervention. Acta Cardiol. 2014 Dec;69(6):619-27. doi: 10.1080/ac.69.6.1000004.
Results Reference
derived

Learn more about this trial

(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)

We'll reach out to this number within 24 hrs